Gregory L. Verdine - 08 Dec 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Reporting relationship: Director
Issuer ticker: WVE
Reported as of: 08 Dec 2025
Net transaction value: -$269,461
SEC form: 4
Accepted by SEC: 10 Dec 2025, 21:45:09 UTC
Prior SEC filing: 26 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Gregory L. Verdine

Key filing fact

Gregory L. Verdine filed Form 4 for Wave Life Sciences Ltd. (WVE) on 10 Dec 2025.

Key facts

This page summarizes Gregory L. Verdine's Form 4 filing for Wave Life Sciences Ltd. (WVE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Dec 2025, 21:45.

Change

Previous filing in this sequence was filed on 26 Aug 2025.
Current net transaction value: -$269,461.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001572315 Primary reporting owner

Verdine Gregory L.

Relationship: Director
Address: C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Gregory L. Verdine
Signature date: 10 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Ordinary Shares

Sale

Transaction value: $157,342
Shares: -12,020
Change %: -4.1%
Price: $13.09
Shares after: 283,197
Date: 08 Dec 2025
Ownership: Direct
Footnotes: F1, F2

WVE transaction

Ordinary Shares

Sale

Transaction value: $112,119
Shares: -7,980
Change %: -2.8%
Price: $14.05
Shares after: 275,217
Date: 08 Dec 2025
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

Footnote F2

The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.74 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Footnote F3

The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.70 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price